Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
Clinical trial NCT06379399 · UNKNOWN
Trial details
- NCT number
- NCT06379399
- Sponsor
- Wangxia LV
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-01
- Primary completion
- 2025-03-01
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.